ClinicalTrials.gg
CompletedNCT00191308Updated Oct 21, 2011Results posted

Molecular Profiling in Lung Cancer Patients

A Phase 2 interventional study of pemetrexed and cisplatin in Non-Small Cell Lung Cancer and Carcinoma, sponsored by Eli Lilly and Company. Completed at 3 sites in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-10-21.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 33 under way, 12 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.

Enrollment
159th of 224
30 · median 65
Started
2005
with 19 others
Phase 2
128 of 228
12 open now
Registered
13th of 228
by date
Lead sponsor
40 of 228
Eli Lilly and Company

Among the 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 159th largest by enrollment of the 224 interventional ones that give a count, is one of 20 that started in 2005, is one of 128 in phase 2, and was the 13th registered.

Carcinoma, Non-Small-Cell Lung

7,638 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

22 of the 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The main purpose of this study of pemetrexed combined with cisplatin used as neoadjuvant chemotherapy (2 or 3 cycles) in participants with operable non-small cell lung cancer (NSCLC) is to look at various genes present in participants' blood and tumor tissue to see if there is any link between the levels or changes in the genes and how participants with lung cancer respond to pemetrexed and cisplatin treatment.

03

Conditions studied

  • Non-Small Cell Lung Cancer
  • Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • pathologic documentation of non-small cell lung cancer (NSCLC)
  • tumor must be accessible by bronchoscopy for tumor tissue sample collection
  • patients must have lung cancer with clinical stage IB, II, IIIA
  • (ECOG) performance status 0 or 1
  • patients must not have received prior systemic chemotherapy or radiation therapy for NSCLC (prior resection of lung is allowed provided at least 5 years have elapsed between prior surgery and enrolment)

Exclusion criteria

Exclusion Criteria:

  • bronchoalveolar carcinoma or stage IIIA tumor involving the superior sulcus (Pancoast tumors)
  • pregnant or breast feeding patients
  • patients who have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry
  • patients with history or presence of other except in situ carcinoma of the skin or prior malignancy treated more than 5 years before without recurrence (excluding melanoma, breast cancer and hypernephroma)
  • unwillingness to take folic acid or vitamin B12 supplementation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Pemetrexed + Cisplatin

    Pemetrexed: 500 milligrams per square meter (mg/m\^2) intravenous (IV) every 21 days (q 21 days) for 3 cycles unless disease progression occurs Cisplatin: 75 mg/m\^2 IV q 21 days for 3 cycles unless disease progression occurs

    Drug: pemetrexed · Drug: cisplatin · Procedure: Radical Non-Small Cell Lung Cancer (NSCLC) surgery

Interventions

  • 500 mg/m\^2 IV q 21 days for 3 cycles unless disease progression occurs

    Also known as: LY231514, Alimta

  • 75 mg/m\^2 IV q 21 days for 3 cycles unless disease progression occurs

  • ProcedureRadical Non-Small Cell Lung Cancer (NSCLC) surgery

    All participants proceeded to surgery within 4-8 weeks from the last dose of pemetrexed.

06

What researchers measure

Primary outcomes

  1. High/Low Expression of Selected Molecular Markers in Tumor Tissues and Hypermethylated Genes in Peripheral Blood

    Molecular markers assessed by immunohistochemistry: thymidylate synthase, glycinamide ribonucleotide formyl transferase (GARFT), epidermal growth factor receptor (EGFR); and by polymerase chain reaction: dihydrofolate reductase (DHFR), dihydropyrimidine dehydrogenase (DPD), folylpolyglutamate synthetase (FPGS), reduced folate carrier, alpha folate receptor, Excision Repair Cross-Complementation Group 1 (ERCC1), folylpolyglutamate hydrolase (FPGH). Hypermethylated genes assessed by methylation-specific polymerase chain reaction. Due to small sample size, tumor-tissue analyses were not done.

    Time frame: Baseline, Cycle 2, and surgery (4-8 weeks after last dose of pemetrexed)

Secondary outcomes

  1. Percentage of Participants With Objective Tumor Response (Response Rate)

    Tumor response to treatment using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR)=disappearance of all target lesions; Partial Response (PR)=30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD)=20% increase in sum of longest diameter of target lesions; Stable Disease (SD)=small changes that do not meet above criteria. Response rate was estimated as the total number of CR or PR, divided by the total number of participants treated.

    Time frame: Treatment start to disease progression or surgery (4-8 weeks after last dose of pemetrexed)

  2. Duration of Response

    The duration of response was defined as the time from complete response (CR) or partial response (PR) to disease progression. Complete Response (CR)=disappearance of all target lesions; Partial Response (PR)=30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD)=20% increase in sum of longest diameter of target lesions.

    Time frame: Time of response to disease progression (up to 44.4 months)

  3. Disease Free Survival (DFS)

    DFS was the time from date of first dose to first observation of progressive disease (PD) or death due to any cause. PD=20% increase in sum of longest diameter of target lesions. If a participant was not known to have died or have PD, DFS was censored at the date of the last objective progression-free disease assessment.

    Time frame: Treatment start to disease progression or death from any cause (up to 45.5 months)

  4. Overall Survival (OS)

    OS was defined as the time from treatment start to death from any cause. For participants who were alive, OS was censored at the last contact date.

    Time frame: Treatment start to death from any cause (up to 47.6 months)

07

Results

Posted Apr 20, 2010
Limitations and caveats
Trial enrollment was terminated early due to lack of eligible participants.

Participant flow

Participant flow — Overall Study
MilestonePemetrexed + Cisplatin
Started30
Completed29
Not completed1
Withdrew: Adverse event1

Outcome measures

PrimaryHigh/Low Expression of Selected Molecular Markers in Tumor Tissues and Hypermethylated Genes in Peripheral Blood

Molecular markers assessed by immunohistochemistry: thymidylate synthase, glycinamide ribonucleotide formyl transferase (GARFT), epidermal growth factor receptor (EGFR); and by polymerase chain reaction: dihydrofolate reductase (DHFR), dihydropyrimidine dehydrogenase (DPD), folylpolyglutamate synthetase (FPGS), reduced folate carrier, alpha folate receptor, Excision Repair Cross-Complementation Group 1 (ERCC1), folylpolyglutamate hydrolase (FPGH). Hypermethylated genes assessed by methylation-specific polymerase chain reaction. Due to small sample size, tumor-tissue analyses were not done.

Time frame:
Baseline, Cycle 2, and surgery (4-8 weeks after last dose of pemetrexed)
Reported as:
Number · participants

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Objective Tumor Response (Response Rate)

Tumor response to treatment using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR)=disappearance of all target lesions; Partial Response (PR)=30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD)=20% increase in sum of longest diameter of target lesions; Stable Disease (SD)=small changes that do not meet above criteria. Response rate was estimated as the total number of CR or PR, divided by the total number of participants treated.

Time frame:
Treatment start to disease progression or surgery (4-8 weeks after last dose of pemetrexed)
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Tumor Response (Response Rate)
percentage of participantsPemetrexed + Cisplatin
Percentage of Participants With Objective Tumor Response (Response Rate)34.5 (17.9 to 54.3)
SecondaryDuration of Response

The duration of response was defined as the time from complete response (CR) or partial response (PR) to disease progression. Complete Response (CR)=disappearance of all target lesions; Partial Response (PR)=30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD)=20% increase in sum of longest diameter of target lesions.

Time frame:
Time of response to disease progression (up to 44.4 months)
Reported as:
Median · months
Duration of Response
monthsPemetrexed + Cisplatin
Duration of Response42.5 (8.31 to NA)
SecondaryDisease Free Survival (DFS)

DFS was the time from date of first dose to first observation of progressive disease (PD) or death due to any cause. PD=20% increase in sum of longest diameter of target lesions. If a participant was not known to have died or have PD, DFS was censored at the date of the last objective progression-free disease assessment.

Time frame:
Treatment start to disease progression or death from any cause (up to 45.5 months)
Reported as:
Median · months
Disease Free Survival (DFS)
monthsPemetrexed + Cisplatin
Disease Free Survival (DFS)43.7 (25.36 to NA)
SecondaryOverall Survival (OS)

OS was defined as the time from treatment start to death from any cause. For participants who were alive, OS was censored at the last contact date.

Time frame:
Treatment start to death from any cause (up to 47.6 months)
Reported as:
Median · months
Overall Survival (OS)
monthsPemetrexed + Cisplatin
Overall Survival (OS)NA (31.15 to NA)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemetrexed + Cisplatin—4/30 (13.3%)19/30 (63.3%)
Most frequent serious events
Most frequent serious events
EventPemetrexed + Cisplatin
Bronchopleural fistulaRespiratory, thoracic and mediastinal disorders2/30
Gastric ulcerGastrointestinal disorders1/30
Post procedural haemorrhageInjury, poisoning and procedural complications1/30
Most frequent other events
Most frequent other events
EventPemetrexed + Cisplatin
Alanine aminotransferase increasedInvestigations4/30
Aspartate aminotransferase increasedInvestigations4/30
Weight increasedInvestigations4/30
HyperkalaemiaMetabolism and nutrition disorders3/30
HypernatraemiaMetabolism and nutrition disorders2/30
RashSkin and subcutaneous tissue disorders2/30

Baseline characteristics

Age Continuous
Age Continuous(years)Pemetrexed + Cisplatin
Mean55.94 ± 8.214
Sex: Female, Male
Sex: Female, Male(Participants)Pemetrexed + Cisplatin
Female1
Male29
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Pemetrexed + Cisplatin
Caucasian30
Region of Enrollment
Region of Enrollment(participants)Pemetrexed + Cisplatin
Poland30
Basis for Diagnosis
Basis for Diagnosis(participants)Pemetrexed + Cisplatin
Histopathological30
Cytological0
Initial Pathological Diagnosis
Initial Pathological Diagnosis(participants)Pemetrexed + Cisplatin
Adenocarcinoma of Lung2
Mixed Cell Carcinoma of Lung0
Squamous Cell Carcinoma of Lung20
Large Cell Carcinoma of Lung0
Bronchoalveolar Carcinoma0
Other8
Stage of Disease at Study Entry
Stage of Disease at Study Entry(participants)Pemetrexed + Cisplatin
Stage IB18
Stage IIA2
Stage IIB10
08

Study locations

3 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bystra Slaska, 43-360, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Poznan, 60-569, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Warsaw, 02-781, Poland
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2005, a primary completion of Jul 2008 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2010, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 19, 2005
Start
May 2005
Primary completionActual
Jul 2008
CompletionActual
Dec 2010
Results first posted
Apr 20, 2010
Last update
Oct 21, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00191308
Responsible party
Sponsor
First posted
Sep 19, 2005
Start date
May 2005
Primary completion
Jul 2008
Completion
Dec 2010
Results posted
Apr 20, 2010
Last update
Oct 21, 2011

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/ GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pemetrexed · Cisplatin

Start the discussion